0.4324
price up icon3.62%   0.0151
after-market Handel nachbörslich: .44 0.0076 +1.76%
loading

Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten

pulisher
Apr 02, 2025

LCTX Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Apr 02, 2025
pulisher
Mar 27, 2025

LCTX stock touches 52-week low at $0.48 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Lineage Cell Therapeutics : Wave Life Sciences Announces Positive Data from FORWARD 53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE N531 - MarketScreener

Mar 27, 2025
pulisher
Mar 25, 2025

Cell Therapy Manufacturing Market Demand, Growth and Future - openPR.com

Mar 25, 2025
pulisher
Mar 18, 2025

LCTX stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

B. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Cell Therapy Manufacturing Market Poised for Expansion Biotech - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail

Mar 12, 2025
pulisher
Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics stock target cut to $3 by Craig-Hallum - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 11, 2025
pulisher
Mar 10, 2025

Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics earnings beat by $0.01, revenue topped estimates - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - BioSpace

Mar 10, 2025
pulisher
Mar 10, 2025

Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Reports Q4 Revenue Growth, FDA Breakthrough Status for Eye Treatment - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Lineage Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 05, 2025

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 - BioSpace

Mar 05, 2025
pulisher
Mar 05, 2025

When Will Lineage Cell Therapeutics Reveal Its 2024 Financial Performance? - Stock Titan

Mar 05, 2025
pulisher
Mar 03, 2025

Atria Wealth Solutions Inc. Makes New Investment in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Mar 03, 2025
pulisher
Feb 28, 2025

Lineage Cell Therapeutics (LCTX) to Release Quarterly Earnings on Thursday - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Lineage Cell Therapeutics (LCTX) to Release Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 18, 2025

Short Interest in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Decreases By 21.4% - MarketBeat

Feb 18, 2025
pulisher
Feb 15, 2025

SG Americas Securities LLC Acquires 18,053 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Cut to $2.00 by Analysts at D. Boral Capital - MarketBeat

Feb 14, 2025
pulisher
Feb 12, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Lowered to $2.00 at D. Boral Capital - Defense World

Feb 12, 2025
pulisher
Feb 12, 2025

Lineage begins study of OPC1 delivering device for spinal cord injury treatment - Yahoo Finance

Feb 12, 2025
pulisher
Feb 11, 2025

HC Wainwright Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Lineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury -February 11, 2025 at 10:21 am EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Lineage Initiates Clinical Study Of OPC1 For Spinal Cord Injury -February 11, 2025 at 08:46 am EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Market Recap Check: Lineage Cell Therapeutics Inc (LCTX)’s Negative Finish at 0.66, Up/Down -2.12 - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury - Business Wire

Feb 11, 2025
pulisher
Feb 11, 2025

Refrigerated Warehousing Market Revenues to Grow from $85 Billion in 2024 to $241 Billion by 2030 - GlobeNewswire Inc.

Feb 11, 2025
pulisher
Feb 11, 2025

Lineage's Next-Gen Spinal Treatment Targets Both Recent & Long-Term InjuriesMajor Trial Expansion - Stock Titan

Feb 11, 2025
pulisher
Feb 07, 2025

Lineage Cell Therapeutics Inc [LCTX] Shares Fall Approximately -33.17% Over the Year - Knox Daily

Feb 07, 2025
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):